000403 派林生物
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,403,125-13.29%2,632,6072,654,6852,328,7232,405,188
减:营业总成本1,239,3712.92%2,019,4341,815,7281,639,4961,753,334
    其中:营业成本951,4049.53%1,539,1681,350,3981,129,8781,151,443
               财务费用(17,535)-36.63%(36,077)(49,170)(57,572)(55,315)
               资产减值损失(370)-69.81%(100,053)(1,254)--124
公允价值变动收益367-106.33%4,2966,381(18,970)4,929
投资收益4,491-72.10%8,95417,7397,4023,038
    其中:对联营企业和合营企业的投资收益------------
营业利润182,574-57.68%527,210880,313695,188663,429
利润总额174,247-57.18%500,301852,778688,109660,392
减:所得税费用22,676-54.13%80,765107,73676,63672,702
净利润151,570-57.60%419,536745,042611,472587,690
减:非控股权益1,266300.38%270(279)(639)559
股东净利润150,304-57.92%419,266745,321612,111587,131

市场价值指针
每股收益 (元) *0.160-57.89%0.4400.7800.8400.804
每股派息 (元) *0.150----0.5000.2000.080
每股净资产 (元) *8.375-0.83%8.51010.84010.1359.377
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容